Public Release:  Researchers identify therapeutic targets in neurofibromatosis

Journal of Clinical Investigation

Neurofibromatosis-1 (NF1) is an inherited disorder caused by mutations in the NF1 gene that result in the formation of nervous tissue tumors (neurofibromas) in the skin, subcutaneous tissue, and the cranial and spinal root nerves. Additionally, NF1 patients are predisposed to juvenile myelomonocytic leukemia (JMML), myeloproliferative disorders, and malignant peripheral nerve sheath tumors (MPNST). NF1 encodes a protein that serves as a negative regulator of a signaling pathway composed of RAS, RAF, MEK, and ERK proteins, known as MAPK signaling cascades. Cells expressing mutated NF1 exhibit hyperactivation of these signaling pathways.

In this issue of the Journal of Clinical Investigation, three independent groups of researchers report that MAPK hyperactivation is a critical mediator of disease pathogenesis in neurofibromatosis. Researchers led by Wade Clapp at Indiana University found that disruption of ERK signaling blocked the development of JMML in NF1 mutant mice. Similarly, Kevin Shannon and colleagues at the University of California, San Francisco, determined that inhibition of the MAPK signaling cascade component, MEK, reduced the growth of NF1-associated peripheral nerve tumors in mice. MEK inhibition was also shown to ameliorate NF1-associated murine myeloproliferative disorders by Nancy Ratner's research group at Cincinnati Children's Hospital Medical Center. Taken together, these studies demonstrate that hyperactivation of MEK and ERK underlies NF1-associated disorders and provide a rationale for testing MEK and ERK inhibitors in neurofibromatosis patients.

###

TITLE:
Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require ERK

AUTHOR CONTACT:
D. Wade Clapp
Indiana University, Indianapolis, IN, USA
Phone: 317-278-9290; Fax: 317-274-8679; E-mail: dclapp@iupui.edu

ACCOMPANYING ARTICLE

TITLE:
Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice

AUTHOR CONTACT:
Kevin Shannon
UCSF, San Francisco, CA, USA
Phone: 415-476-7932; E-mail: shannonk@peds.ucsf.edu

ACCOMPANYING ARTICLE

TITLE:
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors

AUTHOR CONTACT:
Nancy Ratner
Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
Phone: 513-636-9469; Fax: 513-636-3549; E-mail: nancy.ratner@cchmc.org

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.